<DOC>
	<DOCNO>NCT00404729</DOCNO>
	<brief_summary>In management glaucoma , optic nerve disease , important goal ophthalmologist represent possibility influence visual function . In regard , Parisi et al [ Ophthalmology 1999 ; 106:1126-1134 . ] suggest intramuscular treatment Cytidine-5-diphosphocholine ( CDP-Choline citicoline ) improve glaucomatous visual defect . In particular , recent study report effect citicoline glaucomatous retinal postretinal visual structure evaluate electrophysiological examination ( PERG VEP ) . It observe 2-month period treatment citicoline may induce improvement ganglion cell function ( PERGs increase amplitude shorten times-to-peak ) neural conduction along postretinal visual pathway ( VEPs increase amplitude shorten times-to-peak ) . The effect citicoline glaucomatous retinal postretinal structure present 8 month end treatment . However , perform several 2-month period treatment citicoline total period 8 year , find additional improvement glaucomatous retinal postretinal impairment [ Parisi V. Doc Ophthalmol . 2005 Jan ; 110:91-102 ) . In work , aim ass whether similar visual function outcome reach oral treatment citicoline patient affect glaucomatous optic nerve disease optic nerve disease ( i.e . non-arteritic ischemic optic neuropathy )</brief_summary>
	<brief_title>Neural Conduction Along Visual Pathways After Oral Treatment With Citicoline Patients With Optic Nerve Diseases</brief_title>
	<detailed_description>Participants : 30 patient open-angle glaucoma ( OAG ) 15 patient ( mean age 64.6±3.3ys ) non-arteritic ischemic optic neuropathy ( NION ) enrol enrol . Ten OAG patient untreated ( NT-AOG , 10 eye ) , 20 OAG patient ( T-AOG , 20 eye ) 15 NION patient ( T-NION , 14 eye ) treat Citicoline ( oral treatment:1600 mg/die per 60 day ) ( Cebrolux® , Tubilux , Italy ) . Methods : In T-OAG , NT-OAG T-NION patient , Visual Evoked Potentials ( VEPs ) record response 15 ’ checkerboard pattern stimulus . VEPs assess 5 time total period 360 day : baseline condition ( 0 day ) , two different cycle 60 day treatment ( day 0-60 day 180-240 ) , two different cycle 120 day wash ( day 60-180 240-360 ) . In NT-AOG patient , VEPs assess baseline condition ( 0 day ) 60 , 180 , 240 360 day .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Optic Nerve Diseases</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Optic Neuropathy , Ischemic</mesh_term>
	<mesh_term>Cytidine Diphosphate Choline</mesh_term>
	<criteria>Glaucoma Patients : IOP &gt; 23 mmHg &lt; 28 mmHg ( average two high reading daily curve , 8:00 a.m. 6:00 p.m. , six independent reading , one every two hour ) without medical treatment ; HFA MD &lt; 2 dB ; CPSD &gt; +2 dB ; fixation loss , false positive rate false negative rate le 20 % ; best correct visual acuity 20/20 good ; one papillary sign conventional color stereoslides : presence localize loss neuroretinal rim ( notch ) , thin neuroretinal rim , generalize loss optic rim tissue , optic disc excavation , vertical horizontal cup/disc ratio great 0.5 , cupdisc asymmetry two eye great 0.2 , peripapillary splinter hemorrhage ; refractive error ( present ) 1.00 +1.00 spherical equivalent ; previous history presence disease involve cornea , lens , macula retina ; previous history presence diabetes , optic neuritis , disease involve visual pathway ; pupil diameter &gt; 3 mm without mydriatic miotic drug . Patients nonarteritic ischemic optic neuropathy : IOP &lt; 21 mmHg HFA MD &lt; 2 dB ; CPSD &gt; +2 dB ; fixation loss , false positive rate false negative rate le 20 % ; refractive error ( present ) 1.00 +1.00 spherical equivalent ; previous history presence disease involve cornea , lens , macula retina ; previous history presence diabetes disease involve visual pathway ; pupil diameter &gt; 3 mm without mydriatic miotic drug . All condition may influence Visual Evoked Potentials : previous history presence disease involve cornea , lens , macula retina optic nerve ( i.e inflammatory disease )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Glaucoma</keyword>
	<keyword>Optic Neuropathy , Ischemic</keyword>
	<keyword>Visual Pathways ,</keyword>
	<keyword>Optic nerve</keyword>
	<keyword>Neural conduction</keyword>
</DOC>